<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Insulin NPH - Comprehensive Guide</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css">
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
        }
        
        :root {
            --primary: #1a73e8;
            --secondary: #34a853;
            --accent: #fbbc05;
            --dark: #2c3e50;
            --light: #f8f9fa;
            --danger: #ea4335;
        }
        
        body {
            background: linear-gradient(135deg, #f5f7fa 0%, #e4edf5 100%);
            color: #333;
            line-height: 1.6;
        }
        
        header {
            background: linear-gradient(to right, var(--primary), var(--secondary));
            color: white;
            padding: 2rem;
            text-align: center;
            box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            position: relative;
            overflow: hidden;
        }
        
        header::before {
            content: "";
            position: absolute;
            top: -50%;
            left: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, rgba(255,255,255,0) 70%);
            transform: rotate(30deg);
        }
        
        .logo-container {
            display: flex;
            align-items: center;
            justify-content: center;
            margin-bottom: 1rem;
        }
        
        .logo {
            font-size: 3rem;
            margin-right: 1rem;
            animation: pulse 2s infinite;
        }
        
        h1 {
            font-size: 2.8rem;
            margin-bottom: 0.5rem;
            text-shadow: 2px 2px 4px rgba(0,0,0,0.2);
        }
        
        .subtitle {
            font-size: 1.2rem;
            max-width: 800px;
            margin: 0 auto;
            opacity: 0.9;
        }
        
        .container {
            max-width: 1200px;
            margin: 2rem auto;
            padding: 0 1.5rem;
        }
        
        .card {
            background: white;
            border-radius: 12px;
            box-shadow: 0 6px 15px rgba(0,0,0,0.08);
            padding: 2rem;
            margin-bottom: 2rem;
            transition: transform 0.3s ease, box-shadow 0.3s ease;
            border-top: 4px solid var(--primary);
        }
        
        .card:hover {
            transform: translateY(-5px);
            box-shadow: 0 12px 25px rgba(0,0,0,0.15);
        }
        
        h2 {
            color: var(--primary);
            margin-bottom: 1.5rem;
            padding-bottom: 0.75rem;
            border-bottom: 2px solid #eaeaea;
            display: flex;
            align-items: center;
        }
        
        h2 i {
            margin-right: 12px;
            background: linear-gradient(to right, var(--primary), var(--secondary));
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
        }
        
        h3 {
            color: var(--secondary);
            margin: 1.5rem 0 0.75rem;
        }
        
        p {
            margin-bottom: 1rem;
        }
        
        ul, ol {
            margin: 1rem 0;
            padding-left: 1.5rem;
        }
        
        li {
            margin-bottom: 0.5rem;
        }
        
        .highlight {
            background: linear-gradient(120deg, rgba(26, 115, 232, 0.1), rgba(52, 168, 83, 0.1));
            padding: 1.5rem;
            border-radius: 10px;
            margin: 1.5rem 0;
            border-left: 4px solid var(--secondary);
        }
        
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 1.5rem 0;
            background: white;
            border-radius: 10px;
            overflow: hidden;
            box-shadow: 0 4px 10px rgba(0,0,0,0.05);
        }
        
        th {
            background: linear-gradient(to right, var(--primary), var(--secondary));
            color: white;
            text-align: left;
            padding: 1rem;
        }
        
        td {
            padding: 1rem;
            border-bottom: 1px solid #eee;
        }
        
        tr:nth-child(even) {
            background-color: #f8f9fa;
        }
        
        tr:hover {
            background-color: #f1f8ff;
        }
        
        .pill {
            display: inline-block;
            padding: 0.3rem 0.8rem;
            background: var(--accent);
            color: #333;
            border-radius: 20px;
            font-size: 0.85rem;
            margin: 0.2rem;
            font-weight: 600;
        }
        
        .references {
            background: var(--dark);
            color: white;
            padding: 3rem 0;
            margin-top: 2rem;
        }
        
        .references h2 {
            color: white;
            border-bottom: 2px solid rgba(255,255,255,0.2);
        }
        
        .ref-list {
            list-style-type: none;
            padding: 0;
        }
        
        .ref-list li {
            margin-bottom: 1rem;
            padding-left: 1.5rem;
            position: relative;
        }
        
        .ref-list li::before {
            content: "•";
            position: absolute;
            left: 0;
            color: var(--accent);
            font-size: 1.5rem;
        }
        
        footer {
            text-align: center;
            padding: 2rem;
            background: #1a1a2e;
            color: #aaa;
            font-size: 0.9rem;
        }
        
        .info-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 1.5rem;
            margin-top: 1.5rem;
        }
        
        .info-box {
            background: #f0f7ff;
            padding: 1.5rem;
            border-radius: 10px;
            border-left: 4px solid var(--primary);
        }
        
        .info-box h4 {
            color: var(--primary);
            margin-bottom: 0.5rem;
        }
        
        .warning {
            background: #fff8e6;
            border-left: 4px solid var(--accent);
            padding: 1rem;
            border-radius: 0 8px 8px 0;
            margin: 1.5rem 0;
        }
        
        .warning h4 {
            color: var(--accent);
            display: flex;
            align-items: center;
        }
        
        .warning h4 i {
            margin-right: 10px;
        }
        
        @keyframes pulse {
            0% { transform: scale(1); }
            50% { transform: scale(1.1); }
            100% { transform: scale(1); }
        }
        
        .section-nav {
            display: flex;
            flex-wrap: wrap;
            gap: 0.5rem;
            margin: 1.5rem 0;
        }
        
        .nav-btn {
            padding: 0.7rem 1.5rem;
            background: white;
            border: 2px solid var(--primary);
            color: var(--primary);
            border-radius: 30px;
            font-weight: 600;
            cursor: pointer;
            transition: all 0.3s ease;
        }
        
        .nav-btn:hover {
            background: var(--primary);
            color: white;
        }
        
        @media (max-width: 768px) {
            h1 {
                font-size: 2.2rem;
            }
            
            .container {
                padding: 0 1rem;
            }
            
            .card {
                padding: 1.5rem;
            }
        }
    </style>
</head>
<body>
    <header>
        <div class="logo-container">
            <div class="logo">
                <i class="fas fa-syringe"></i>
            </div>
            <div>
                <h1>Insulin NPH (Neutral Protamine Hagedorn)</h1>
                <p class="subtitle">A comprehensive guide to pharmacology, dosing, mechanism, and clinical use</p>
            </div>
        </div>
    </header>
    
    <div class="container">
        <div class="section-nav">
            <button class="nav-btn" onclick="scrollToSection('generic')">Generic Info</button>
            <button class="nav-btn" onclick="scrollToSection('chemistry')">Chemistry</button>
            <button class="nav-btn" onclick="scrollToSection('pharmacokinetics')">Pharmacokinetics</button>
            <button class="nav-btn" onclick="scrollToSection('indications')">Indications</button>
            <button class="nav-btn" onclick="scrollToSection('mechanism')">Mechanism</button>
            <button class="nav-btn" onclick="scrollToSection('storage')">Storage</button>
            <button class="nav-btn" onclick="scrollToSection('pakistan')">Pakistan Formulations</button>
            
<button class="nav-btn" onclick="scrollToSection('side-effects')">Side Effects</button>
<button class="nav-btn" onclick="scrollToSection('time-curve')">Time-Action Curve</button>

            <button class="nav-btn" onclick="scrollToSection('references')">References</button>
        </div>
        
        <div class="card" id="generic">
            <h2><i class="fas fa-info-circle"></i> Generic Information</h2>
            <div class="info-grid">
                <div class="info-box">
                    <h4>Generic Name</h4>
                    <p>Insulin NPH (Neutral Protamine Hagedorn) or isophane insulin</p>
                </div>
                <div class="info-box">
                    <h4>Brand Names</h4>
                    <p>Humulin N (Eli Lilly), Novolin N (Novo Nordisk), Insulatard (Sanofi), Gensulin N</p>
                </div>
                <div class="info-box">
                    <h4>Classification</h4>
                    <p>Intermediate-acting insulin (duration: 14–24 hours)</p>
                </div>
                <div class="info-box">
                    <h4>Regulatory Status</h4>
                    <p>WHO Essential Medicine, Prescription-only in the US/EU</p>
                </div>
            </div>
        </div>
        
        <div class="card" id="chemistry">
            <h2><i class="fas fa-flask"></i> Chemistry</h2>
            <p>Insulin NPH is a suspension of recombinant human insulin complexed with protamine and zinc at neutral pH (7.0–7.5).</p>
            
            <div class="highlight">
                <h3>Key Chemical Properties</h3>
                <ul>
                    <li><strong>Protamine source:</strong> Basic protein derived from salmon sperm</li>
                    <li><strong>Appearance:</strong> Cloudy suspension due to crystalline microstructure</li>
                    <li><strong>Formulation ratio:</strong> Protamine to insulin ratio of 1:5–1:10 to delay absorption</li>
                    <li><strong>Preparation:</strong> Requires thorough resuspension before administration</li>
                </ul>
            </div>
            
            <div class="warning">
                <h4><i class="fas fa-exclamation-triangle"></i> Important Note</h4>
                <p>NPH insulin should never be administered intravenously due to the risk of severe adverse reactions from the protamine component.</p>
            </div>
        </div>
        
        <div class="card" id="pharmacokinetics">
            <h2><i class="fas fa-chart-line"></i> Pharmacokinetics (LADME)</h2>
            
            <table>
                <thead>
                    <tr>
                        <th>Parameter</th>
                        <th>Value</th>
                        <th>Influencing Factors</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Liberation</strong></td>
                        <td>Slow dissolution of insulin-protamine-zinc crystals at subcutaneous site</td>
                        <td>Injection technique, tissue characteristics</td>
                    </tr>
                    <tr>
                        <td><strong>Absorption</strong></td>
                        <td>Onset: 1–3 hours; Peak: 4–8 hours; Duration: 14–24 hours</td>
                        <td>Injection site, exercise, resuspension technique</td>
                    </tr>
                    <tr>
                        <td><strong>Distribution</strong></td>
                        <td>Rapid extracellular distribution; does not cross placenta</td>
                        <td>Body composition, circulatory status</td>
                    </tr>
                    <tr>
                        <td><strong>Metabolism</strong></td>
                        <td>Primarily hepatic (60–80%), also renal and muscular</td>
                        <td>Liver and kidney function</td>
                    </tr>
                    <tr>
                        <td><strong>Excretion</strong></td>
                        <td>Renal (30–80% as metabolites)</td>
                        <td>Renal function, glomerular filtration rate</td>
                    </tr>
                </tbody>
            </table>
            
            <div class="highlight">
                <h3>Clinical Significance</h3>
                <p>Improper resuspension of NPH insulin before injection can increase pharmacokinetic variability by up to 23% (measured by AUC). This is why it's essential to roll the vial or pen between hands until the suspension appears uniformly cloudy.</p>
            </div>
        </div>
        
        <div class="card" id="indications">
            <h2><i class="fas fa-prescription-bottle-medical"></i> Indications and Dosing</h2>
            
            <h3>Approved Uses</h3>
            <ul>
                <li>Type 1 diabetes (as basal insulin component)</li>
                <li>Type 2 diabetes (when oral hypoglycemic agents fail to achieve glycemic control)</li>
                <li>Gestational diabetes mellitus (when insulin therapy is required)</li>
            </ul>
            
            <h3>Dosing Guidelines</h3>
            <table>
                <thead>
                    <tr>
                        <th>Population</th>
                        <th>Dosing</th>
                        <th>Administration</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Adults (Type 1)</strong></td>
                        <td>0.4–1.0 units/kg/day, typically split twice daily</td>
                        <td>Inject subcutaneously 15 mins pre-meal</td>
                    </tr>
                    <tr>
                        <td><strong>Adults (Type 2)</strong></td>
                        <td>Start at 0.2 units/kg/day, titrate based on response</td>
                        <td>Inject subcutaneously, usually with breakfast and dinner</td>
                    </tr>
                    <tr>
                        <td><strong>Children (≥12 years)</strong></td>
                        <td>0.5–1.0 units/kg/day</td>
                        <td>Adjust based on growth, activity, and dietary patterns</td>
                    </tr>
                </tbody>
            </table>
            
            <div class="highlight">
                <h3>Typical Dosing Schedule</h3>
                <p>For twice-daily administration:</p>
                <ul>
                    <li><strong>Morning dose:</strong> 2/3 of total daily dose (with ratio of 1:2 rapid-acting insulin to NPH)</li>
                    <li><strong>Evening dose:</strong> 1/3 of total daily dose (with ratio of 1:1 rapid-acting insulin to NPH)</li>
                </ul>
            </div>
        </div>
        
        <div class="card" id="mechanism">
            <h2><i class="fas fa-cogs"></i> Mechanism of Action</h2>
            
            <h3>Glucose Regulation</h3>
            <p>Insulin NPH binds to insulin receptors on target cells, activating a signaling cascade that promotes GLUT4 translocation to the cell membrane, facilitating cellular glucose uptake.</p>
            
            <h3>Metabolic Effects</h3>
            <div class="info-grid">
                <div class="info-box">
                    <h4>Liver</h4>
                    <ul>
                        <li>Inhibits gluconeogenesis and glycogenolysis</li>
                        <li>Promotes glycogen synthesis</li>
                    </ul>
                </div>
                <div class="info-box">
                    <h4>Muscle</h4>
                    <ul>
                        <li>Stimulates glycogen synthesis</li>
                        <li>Enhances protein synthesis</li>
                        <li>Facilitates amino acid uptake</li>
                    </ul>
                </div>
                <div class="info-box">
                    <h4>Adipose Tissue</h4>
                    <ul>
                        <li>Enhances triglyceride storage</li>
                        <li>Suppresses lipolysis</li>
                        <li>Inhibits release of free fatty acids</li>
                    </ul>
                </div>
            </div>
            
            <div class="highlight">
                <h3>Time-Action Profile</h3>
                <p>The intermediate action profile of NPH insulin makes it suitable as a basal insulin, providing background insulin coverage between meals and overnight. Its peak effect typically occurs between 4-8 hours after administration, which requires careful meal planning to prevent hypoglycemia.</p>
            </div>
        </div>
        
        
<div class="card" id="side-effects">
    <h2><i class="fas fa-exclamation-circle"></i> Side Effects & Contraindications</h2>

    <h3>Common Adverse Effects</h3>
    <ul>
        <li>Hypoglycemia (most frequent)</li>
        <li>Weight gain</li>
        <li>Injection site lipodystrophy or lipoatrophy</li>
    </ul>

    <h3>Rare / Serious Reactions</h3>
    <ul>
        <li>Systemic allergic reactions (urticaria, bronchospasm, hypotension)</li>
        <li>Insulin edema syndrome</li>
        <li>Antibody formation (can alter pharmacokinetics)</li>
    </ul>

    <h3>Contraindications</h3>
    <ul>
        <li>Known hypersensitivity to insulin NPH or protamine</li>
        <li>Hypoglycemia (do not administer during episodes)</li>
    </ul>

    <div class="warning">
        <h4><i class="fas fa-triangle-exclamation"></i> Clinical Tip</h4>
        <p>To minimize lipodystrophy, rotate injection sites regularly. For patients with recurrent nocturnal hypoglycemia, consider switching to insulin glargine or detemir.</p>
    </div>
</div>

<div class="card" id="time-curve">
    <h2><i class="fas fa-chart-area"></i> Time-Action Curve</h2>
    <p>This graph illustrates the pharmacodynamic profile of NPH insulin compared to other insulin types.</p>
    <img src="https://www.pharmacologyweekly.com/wp-content/uploads/2018/11/Insulin-action-profile-chart.jpg" alt="Insulin Time-Action Profile" style="width:100%; border-radius: 12px; margin-top: 1rem; box-shadow: 0 4px 12px rgba(0,0,0,0.1);">
</div>

<div class="card" id="storage">
            <h2><i class="fas fa-temperature-low"></i> Stability and Storage</h2>
            
            <div class="info-grid">
                <div class="info-box">
                    <h4>Unopened Vials/Pens</h4>
                    <ul>
                        <li>Refrigerate at 2–8°C (36–46°F)</li>
                        <li>Keep in original packaging</li>
                        <li>Stable until expiration date</li>
                        <li>Avoid freezing</li>
                    </ul>
                </div>
                <div class="info-box">
                    <h4>In-Use Vials/Pens</h4>
                    <ul>
                        <li>Stable at 15–30°C (59–86°F) for 28 days</li>
                        <li>Do not refrigerate after opening</li>
                        <li>Keep away from direct sunlight</li>
                        <li>Do not store with needle attached</li>
                    </ul>
                </div>
            </div>
            
            <div class="warning">
                <h4><i class="fas fa-exclamation-triangle"></i> Emergency Handling</h4>
                <p>If exposed to temperatures >86°F (30°C), the insulin may be used temporarily but blood glucose should be monitored closely and the insulin replaced as soon as possible. Do not use if frozen, discolored, or containing particles.</p>
            </div>
        </div>
        
        <div class="card" id="pakistan">
            <h2><i class="fas fa-map-marker-alt"></i> Common Formulations in Pakistan</h2>
            
            <table>
                <thead>
                    <tr>
                        <th>Formulation Type</th>
                        <th>Examples</th>
                        <th>Availability</th>
                        <th>Affordability</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Human Insulin (NPH)</strong></td>
                        <td>Humulin N, Novolin N</td>
                        <td>90% (private); 50% (public)</td>
                        <td>1.38 days' wages/month</td>
                    </tr>
                    <tr>
                        <td><strong>Insulin Analogs</strong></td>
                        <td>Insulatard</td>
                        <td>62.5% (private)</td>
                        <td>5.06 days' wages/month</td>
                    </tr>
                    <tr>
                        <td><strong>Biosimilars</strong></td>
                        <td>Gan & Lee glargine (approved 2022)</td>
                        <td>Emerging</td>
                        <td>~1.0 day's wages/month (estimated)</td>
                    </tr>
                </tbody>
            </table>
            
            <div class="highlight">
                <h3>Market Challenges in Pakistan</h3>
                <ul>
                    <li><strong>High cost:</strong> Insulin analogs cost 3-4 times more than human insulin</li>
                    <li><strong>Supply chain gaps:</strong> Particularly in rural areas and public sector facilities</li>
                    <li><strong>Import dependence:</strong> 87.5% of market dominated by multinational brands</li>
                    <li><strong>Public sector availability:</strong> Less than 50% compared to WHO target of 80%</li>
                </ul>
            </div>
            
            <div class="info-box">
                <h4>Regulatory Developments</h4>
                <p>The Drug Regulatory Authority of Pakistan (DRAP) is promoting biosimilars and local manufacturing to improve accessibility. The 2022 approval of Gan & Lee's insulin glargine represents a step toward more affordable alternatives.</p>
            </div>
        </div>
    </div>
    
    <div class="references" id="references">
        <div class="container">
            <h2><i class="fas fa-book"></i> References</h2>
            <ul class="ref-list">
                <li>World Health Organization. (2023). WHO Model List of Essential Medicines - 23rd List.</li>
                <li>DrugBank Online. (2023). Insulin Human - DrugBank Accession Number DB00030.</li>
                <li>Kalra S, et al. (2020). Insulin Storage: A Critical Reappraisal. Journal of Diabetes Science and Technology, 14(2), 371-378.</li>
                <li>Feingold KR, et al. (2023). Insulin - Pharmacology, Therapeutic Regimens and Principles of Intensive Insulin Therapy. Endotext [Internet].</li>
                <li>American Diabetes Association. (2023). Standards of Medical Care in Diabetes. Diabetes Care, 46(Supplement 1).</li>
                <li>Bardal SK, et al. (2011). Applied Pharmacology. Elsevier Health Sciences.</li>
                <li>Owens DR. (2022). The Evolution of Insulin Formulations and Delivery Devices: Reflections and Perspectives. Acta Diabetologica, 59(1), 1-10.</li>
                <li>Kaarsholm NC, et al. (2007). Structural Characterization of Insulin NPH Formulations. European Journal of Pharmaceutical Sciences, 30(5), 421-429.</li>
                <li>Pakistan Endocrine Society. (2022). Clinical Practice Guidelines for Diabetes Management in Pakistan.</li>
                <li>Drug Regulatory Authority of Pakistan. (2022). National List of Essential Medicines.</li>
                <li>International Diabetes Federation. (2021). IDF Diabetes Atlas - 10th Edition.</li>
                <li>RxList. (2023). Insulin NPH Side Effects Drug Center.</li>
            </ul>
        </div>
    </div>
    
    <footer>
        <div class="container">
            <p>This educational resource is for academic purposes only. Always consult healthcare professionals for medical advice.</p>
            <p>Designed for Pharmacology Assignment | © 2023 Medical Information Portal</p>
        </div>
    </footer>

    <script>
        function scrollToSection(sectionId) {
            const element = document.getElementById(sectionId);
            if (element) {
                element.scrollIntoView({ behavior: 'smooth', block: 'start' });
            }
        }
        
        // Add active class to nav buttons when section is in view
        window.addEventListener('scroll', function() {
            const sections = document.querySelectorAll('.card, .references');
            const navBtns = document.querySelectorAll('.nav-btn');
            
            let currentSection = '';
            
            sections.forEach(section => {
                const sectionTop = section.offsetTop;
                if (scrollY >= sectionTop - 100) {
                    currentSection = section.id;
                }
            });
            
            navBtns.forEach(btn => {
                btn.classList.remove('active');
                if (btn.getAttribute('onclick').includes(currentSection)) {
                    btn.classList.add('active');
                }
            });
        });
        
        // Add hover effect to cards on mobile
        const cards = document.querySelectorAll('.card');
        cards.forEach(card => {
            card.addEventListener('touchstart', function() {
                this.classList.add('hover');
            });
        });
    </script>
</body>
</html>